RT Journal Article
SR Electronic
T1 Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 990
OP 994
DO 10.1136/jclinpath-2011-200099
VO 64
IS 11
A1 Zaur Hamidov
A1 Annelore Altendorf-Hofmann
A1 Yuan Chen
A1 Utz Settmacher
A1 Iver Petersen
A1 Thomas Knösel
YR 2011
UL http://jcp.bmj.com/content/64/11/990.abstract
AB Background Cell–cell adhesion molecules such as desmosomes and cytokeratins may play a major role in epithelial–mesenchymal transition and have been suggested to have a relevant impact on tumour progression. This study investigated 15 biomarkers in pancreatic ductal adenocarcinoma (PDAC) and correlated the results with clinicopathological parameters.Methods Tissue microarrays of 115 R0-resected PDAC were constructed to evaluate the protein expression of 15 in genome‐wide expression profiling differentially expressed biomarkers.Results At the protein level a high expression of desmocollin 2 (DSC2) was observed in 90.4%, DSC1 (67.6%), DSC3 (0.9%), MDM2 (16.2%), CEA (64.8%), CK7 (85.2%), CK8 (96.5%), CK18 (96.5%), CK19 (93.9%), CK20 (11.5%), CA19-9 (86.6%), TLE1 (8.7%), PITX1 (91.2%), factor H (95.7%) and mesothelin (9.6%). Reduced expression of DSC2 was statistically correlated with shorter patient survival, higher tumour grading and positive lymph node status (p=0.008, p=0.029, p=0.011, respectively). In multivariable analysis reduced expression of DSC2, higher tumour grading and positive lymph node status were independently correlated with shorter patient survival.Conclusions Reduced expression of DSC2 is independently correlated with shorter patient survival, higher tumour grading and positive lymph node status in PDAC and could serve as a prognostic marker.